Zevra Therapeutics Inc. Common Stock (ZVRA)
Stock · NASDAQ · Health Care
$9.93as of 10/16/2026
Price chart
Active signals
ZVRA Signal Track Record
How signals performed across all stocks →What ZVRA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | +0.1% | 50% | October 5, 2026 |
| Bollinger Band Breakout | 27 | -0.7% | 44% | September 2, 2026 |
| 200-Day Moving Average TouchActive now | 20 | -3.3% | 35% | April 1, 2026 |
| Bollinger Band Breakdown | 15 | +3.1% | 53% | October 1, 2026 |
| Any 20-session window (baseline) | +1.3% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ZVRA
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 61
- Website
- zevra.com/
Fundamentals
- 1-day range
- $9.89$10.29
- Market cap
- $702.29M
- P/E (trailing)
- 10.81
- P/E (forward)
- 9.23
- EPS (trailing)
- $0.97
- Dividend yield
- —
- Beta
- 0.97
- Avg. volume
- 1.08M
- Dividend pay date
- December 28, 2020
How Zevra Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 9, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Zevra Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ZVRAZevra Therapeutics Inc. Common Stock$9.94▼ 3.21%Market cap $702.29MP/E 10.81$8.01$15.04
- IMMXImmix Biopharma Inc. Common Stock$7.98▼ 8.06%Market cap $702.09MP/E —$2.31$15.1
- IRWDIronwood Pharmaceuticals Inc. Class A Common Stock$3.5▼ 7.16%Market cap $701.25MP/E 4.68$1.41$5.78
- BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$2.82▼ 4.41%Market cap $703.34MP/E —$3.79$14.87
- EVOEvotec SE American Depositary Shares$1.38▼ 2.82%Market cap $693.72MP/E —$2.41$7.3
- GYREGyre Therapeutics Inc. Common Stock$6.08▼ 5.00%Market cap $713.53MP/E —$5.44$9.42
- HELPCybin Inc. Common Stock$10.55▼ 4.52%Market cap $688.02MP/E —$5.3$20.88
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ZVRA Zevra Therapeutics Inc. Common Stock | $702.29M | 10.81 | $9.94 | ▼ 3.21% | $8.01$15.04 |
| IMMX Immix Biopharma Inc. Common Stock | $702.09M | — | $7.98 | ▼ 8.06% | $2.31$15.1 |
| IRWD Ironwood Pharmaceuticals Inc. Class A Common Stock | $701.25M | 4.68 | $3.5 | ▼ 7.16% | $1.41$5.78 |
| BBOT BridgeBio Oncology Therapeutics Inc. Common Stock | $703.34M | — | $2.82 | ▼ 4.41% | $3.79$14.87 |
| EVO Evotec SE American Depositary Shares | $693.72M | — | $1.38 | ▼ 2.82% | $2.41$7.3 |
| GYRE Gyre Therapeutics Inc. Common Stock | $713.53M | — | $6.08 | ▼ 5.00% | $5.44$9.42 |
| HELP Cybin Inc. Common Stock | $688.02M | — | $10.55 | ▼ 4.52% | $5.3$20.88 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market SessionBenzinga · 10/8/2026
- Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing FactorSeekingAlpha · 10/6/2026
- Rafael Holdings: A Coin Flip With A Second Binary Attached - HoldSeekingAlpha · 10/1/2026
- Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
- Zevra Therapeutics To Present Two Posters Featuring Long-Term Real-World Data On MIPLYFFA For Treatment Of Niemann-Pick Disease Type C At SSIEM Annual Symposiumbenzinga · 8/25/2026
Insider Activity
Insider Actions →- Thompson Rahsaan · August 14, 2026 · Sale42.7K @ $11.13
- Watton Corey Michael · August 10, 2026 · Option Exercise12.3K @ $4.97
- Watton Corey Michael · August 10, 2026 · Sale12.3K @ $11.25
- Thompson Rahsaan · June 22, 2026 · Sale34.6K @ $12.68
- Thompson Rahsaan · June 21, 2026 · Option Exercise66.7K
- Secor Alicia · June 4, 2026 · Grant30.0K
- Watton Corey Michael · June 4, 2026 · Grant30.0K
- Calder Douglas W · June 4, 2026 · Grant30.0K
- Anderson Thomas · June 4, 2026 · Grant30.0K
- Shih Alvin · June 4, 2026 · Grant30.0K
- FAVORITO TAMARA A · June 4, 2026 · Grant30.0K
- Sangiovanni Timothy J. · May 28, 2026 · Grant20.0K
- Sangiovanni Timothy J. · May 28, 2026 · Grant40.0K
- Thompson Rahsaan · May 11, 2026 · Sale1.8K @ $11.3
Institutional Ownership
March 31, 2026
- Total shares held
- 43.32M
- Total value held
- $400.52M
- Institutional holders
- 143
- Unknown4.46M
- Unknown3.45M
- Unknown3.21M
- Unknown2.52M
- Unknown2.47M
- Unknown2.35M
- Unknown1.56M
- Unknown1.37M
- Unknown1.20M
- Unknown1.19M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price
Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price. Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.